Cargando…
Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
BACKGROUND: Dalfampridine has the potential to be effective in patients with transverse myelitis (TM) as this rare disorder shares some clinical and pathogenic similarities with multiple sclerosis. METHODS: This is a randomized, double-blind, placebo-controlled crossover study of dalfampridine exten...
Autores principales: | Schwartz, Kateryna, Wymbs, Nicholas F, Huang, Hwa, Mealy, Maureen A, Pardo, Carlos A, Zackowski, Kathleen, Levy, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731631/ https://www.ncbi.nlm.nih.gov/pubmed/29270309 http://dx.doi.org/10.1177/2055217317740145 |
Ejemplares similares
-
Predictors of recurrence following an initial episode of transverse myelitis
por: Kimbrough, Dorlan J., et al.
Publicado: (2014) -
Familial monophasic acute transverse myelitis due to the pathogenic variant in VPS37A
por: Mealy, Maureen A., et al.
Publicado: (2018) -
Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011) -
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013) -
Transverse Myelitis
por: Lim, Peter A.C.
Publicado: (2020)